238 related articles for article (PubMed ID: 35459760)
1. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
3. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
4. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
[No Abstract] [Full Text] [Related]
5. Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer.
Lee SJ; Oh YT; Jung DC; Cho NH; Choi YD; Park SY
AJR Am J Roentgenol; 2018 Sep; 211(3):W166-W172. PubMed ID: 30016148
[TBL] [Abstract][Full Text] [Related]
6. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
7. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
9. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
10. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
Wang L; Luo Y; Liu T; Deng M; Huang X
Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
[TBL] [Abstract][Full Text] [Related]
11. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Utility of PI-RADS 2.1, ADC Values, and Combined Use of Both, for the Diagnosis of Transition Zone Prostate Cancers.
Liu X; Xiong Q; Zeng W; Yang R; Wen Y; Li X
J Comput Assist Tomogr; 2024 Mar-Apr 01; 48(2):206-211. PubMed ID: 38149651
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
14. [Combination of prostate imaging reporting and data system
with the apparent diffusion coefficient map for the diagnosis of peripheral zone prostate cancer].
Feng Z; Yan Z; Luo M; Liao Y; Rong P; Wang W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 44(3):277-284. PubMed ID: 30971520
[TBL] [Abstract][Full Text] [Related]
15. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
17. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
18. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
19. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
20. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]